Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia.
Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
Life Sci. 2023 Dec 1;334:122182. doi: 10.1016/j.lfs.2023.122182. Epub 2023 Oct 18.
Valproic acid (VPA) belongs to the first-generation antiepileptic drugs, yet its prolonged use can cause life-threatening liver damage. The importance of our study is to investigate the protective effect of indole-3-acetic acid (IAA), chenodeoxycholic acid (CDCA) and their combination on VPA-induced liver injury focusing on lipopolysaccharides (LPS)/toll-like receptor 4 (TLR4) pathway and farnesoid X receptor (FXR).
Thirty rats were randomly assigned into five groups, normal control group, VPA group received 500 mg/kg of VPA intraperitoneally. The remaining groups were orally treated with either 40 mg/kg of IAA, 90 mg/kg of CDCA, or a combination of both, along with VPA. All treatments were administered one hour after the administration of VPA for three weeks.
VPA group showed significant elevations in the liver weight/body weight ratio, serum aminotransferases, triglyceride, and total cholesterol levels. Hepatic glutathione (GSH) level and superoxide dismutase (SOD) activity were significantly decreased, while malondialdehyde (MDA) level, tumor necrosis factor-α (TNF-α), interleukin-1beta (IL-1β), lipopolysaccharide (LPS) and caspase 3 were significantly increased. Likewise, immunohistochemical analysis revealed that TLR4 expression was elevated, whereas FXR expression was downregulated in hepatocytes. IAA substantially ameliorated all previously altered parameters, whereas CDCA treatment showed a partial improvement compared to IAA. Surprisingly, combination therapy of IAA with CDCA showed an additive effect only in the hepatic expression of TLR4 and FXR proteins.
IAA could be a promising protective agent against VPA-induced liver injury.
丙戊酸(VPA)属于第一代抗癫痫药物,但长期使用会导致危及生命的肝损伤。我们研究的重要性在于研究吲哚-3-乙酸(IAA)、鹅去氧胆酸(CDCA)及其组合对 VPA 诱导的肝损伤的保护作用,重点关注脂多糖(LPS)/Toll 样受体 4(TLR4)途径和法尼醇 X 受体(FXR)。
将 30 只大鼠随机分为五组,正常对照组、VPA 组腹腔注射 500mg/kg VPA。其余组分别口服 40mg/kg IAA、90mg/kg CDCA 或两者联合,同时给予 VPA。所有治疗均在 VPA 给药后 1 小时进行,持续 3 周。
VPA 组肝重/体重比、血清转氨酶、甘油三酯和总胆固醇水平显著升高。肝组织谷胱甘肽(GSH)水平和超氧化物歧化酶(SOD)活性显著降低,丙二醛(MDA)水平、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、脂多糖(LPS)和半胱天冬酶 3 显著升高。同样,免疫组化分析显示 TLR4 表达升高,而 FXR 表达在肝细胞中下调。IAA 显著改善了所有先前改变的参数,而 CDCA 治疗与 IAA 相比仅显示部分改善。令人惊讶的是,IAA 与 CDCA 的联合治疗仅在 TLR4 和 FXR 蛋白的肝表达方面表现出相加作用。
IAA 可能是一种有前途的对抗 VPA 诱导的肝损伤的保护剂。